Anemia Clinical Trials

A listing of Anemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 162 clinical trials
Featured trial
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY) (PATHWAY)

The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),

  • 11 views
  • 11 Nov, 2022
  • 39 locations
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of

  • 879 views
  • 23 Oct, 2022
  • 226 locations
Featured trial
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called

  • 380 views
  • 23 Oct, 2022
  • 150 locations
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.

anemia
  • 17 views
  • 19 Dec, 2022
  • 20 locations
Featured trial
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

who are transfusion-dependent or present with symptomatic anemia.

hydroxyurea
carfilzomib
lenalidomide
bortezomib
chronic myelomonocytic leukaemia
  • 1 views
  • 21 Oct, 2022
  • 12 locations
Featured trial
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (LEAP2MONO)  

This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and <18 …

alglucerase
cerezyme
neuronopathic gaucher disease
sterility
replacement therapy
  • 9 views
  • 02 Feb, 2023
  • 1 location
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US  

luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.   The

epoetin alfa
erythropoietin
vasectomy
cancer
  • 54541 views
  • 22 Aug, 2022
  • 9 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. &nbsp

epoetin alfa
  • 23120 views
  • 22 Aug, 2022
  • 10 locations
Featured trial
Sickle Cell Disease Research Study - Fulcrum Therapeutics  

The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.

thalassemia
hemoglobin f
  • 12956 views
  • 31 Jan, 2023
  • 5 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The study is divided into the Screening

epoetin alfa
erythropoietin
vasectomy
cancer
  • 16800 views
  • 22 Aug, 2022
  • 7 locations